LenioBio utilizes its ALiCE® technology for rapid, plant-based, cell-free protein expression, enabling the production of complex proteins within 1-2 days. This scalable system addresses the lengthy timelines and inefficiencies in traditional protein manufacturing, facilitating faster drug development and vaccine production.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cell-based protein expression methods are time-consuming and inefficient, particularly for complex proteins like multi-pass membrane proteins and large protein complexes. These limitations slow down drug development and vaccine production, hindering research and delaying access to life-saving medicines.
Solution
LenioBio's ALiCE® technology offers a rapid, plant-based, cell-free protein expression system that overcomes the limitations of traditional methods. This technology enables the production of functional, complex proteins within 24 hours, significantly accelerating research and development timelines. The ALiCE® system is scalable from research to large-scale production, making it suitable for the entire drug development process. Its open and user-friendly design eliminates the need for lengthy optimization, removing protein expression as a bottleneck.
Target Audience
The primary customers are researchers, drug developers, and vaccine manufacturers seeking faster, more efficient protein expression solutions, particularly for complex or difficult-to-express proteins.
Features
- Rapid protein production within 24 hours, even for complex proteins
- Plant-based, cell-free system minimizing the risk of mammalian contamination
- Scalable from research-scale to large-scale production
- User-friendly, open system requiring minimal optimization
- Suitable for a wide variety of protein targets, including multi-pass membrane proteins and large protein complexes
- ALiCE® for High-Throughput Expression (HTPE) enables rapid antibody production
- Capability to produce proteins for clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days